RLS GLOBAL AB (publ) INTERIM REPORT, Q1, 2020

JANUARY 1st - MARCH 31st

  • Net sales amounted to TSEK 374 (260 TSEK)
  • The operating loss for the period was MSEK -3.9 (-5.7 MSEK)
  • Earnings per share after dilution at SEK -0.06 (-0.04)
  • Cash flow from operating activities amounted to MSEK -4.2 (-5.5 MSEK)
  • Equity ratio was 92 percent (84 percent)

NOTABLE EVENTS DURING THE PERIOD

  • A success for the clinical trial ChloraSolv01 where we have included all patients
  • Revisions of Lloyd’s regarding our quality assurance system and of Eurofins, which is our new Notified Body for directives of medical devices. The revisions resulted good results and new certificates were issued
  • RLS has initiated marketing activities in Norway and Denmark
  • The Board of Directors of RLS decided to sell all intellectual property rights regarding PeriSolv to REGEDENT AG
  • RLS chose Redeye Aktiebolag as the new Certified Advisor
  • RLS was awarded an agreement with the Kalmar Region
  • RLS staff adapt to the new and hold training courses and customer meetings digitally
  • Registration processes in Australia according to plan
  • Continued dialogue with the FDA related to the regulatory path forward in the US

NOTABLE EVENTS AFTER THE PERIOD

  • Notice of the AGM meeting on May 26 has been communicated
  • Sales are starting to gain momentum in the Region of Kalmar
  • Continued dialogue with several Regions, however, decisions are delayed due to Covid-19
  • Contact established at Cardiff University UK and Bispebjerg Hospital, Denmark

COVID-19

  • In the current situation, the Board has considered the impact of different possible future Covid-19 related scenarios
  • Because the healthcare sector is so extremely strained under the prevailing circumstances, all processes take longer which affects our market penetration and other activities, resulting in RLS focusing even more on R&D projects

Trading place and Certified Advisor

RLS Global’s shares has been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.

The Interim Report Q1, 2020 is enclosed and is also available at www.rls.global

Contact information

Karin Fischer, CEO
E-mail:
karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail:
eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop product within wound care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North Growth Market with Redeye Aktiebolag as the Certified Advisor,
phone: +46 8 121 576 90, email:
certifiedadviser@redeye.se. Read more at www.rls.global

About Us

For many years, RLS Global has worked with Oral Care specialists, pioneering new therapies for Oral Care and their patients. We are now taking another major step toward easier and more effective care within Wound Care. We will continue to work with Healthcare Professionals to ensure to develop a treatment that further helps deliver the best care for each patient. The method is clinically proven and saves the patient a lot of suffering. Our focus is on caring for patients, developing efficient and safe products that offer gentle treatment methods.